raloxifene hydrochloride has been researched along with Atrophy in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Conner, EA; Pinkerton, JV | 1 |
| Pinkerton, JV; Stanczyk, FZ | 1 |
| Braga, S; Cannata-Andía, JB; Carrillo-López, N; Fernández-Coto, T; López-Hernández, F; Lopez-Novoa, JM; Naves-Díaz, M; Rodríguez-Rodríguez, A | 1 |
| Eyster, KM; Hansen, KA | 1 |
| Ihoriya, C; Kadoya, H; Kashihara, N; Kidokoro, K; Nagasu, H; Nishi, Y; Sasaki, T; Satoh, M | 1 |
| Goldstein, SR | 1 |
| Heath, H; Merritt, D; Parsons, A; Plouffe, L; Rosen, A; Siddhanti, S | 1 |
| Cosman, F; Lindsay, R; Mikhail, M; Nieves, J; Richart, RM; Scotti, RJ; Vardy, MD; Zion, M | 1 |
| Kessel, B; Nachtigall, L; Parsons, A; Plouffe, L; Rosen, A; Siddhanti, S | 1 |
| Karch, AM; Karch, FE | 1 |
3 review(s) available for raloxifene hydrochloride and Atrophy
| Article | Year |
|---|---|
Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators.
Topics: Adult; Aged; Atrophy; Breast Neoplasms; Estrogens, Conjugated (USP); Female; Female Urogenital Diseases; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Vagina | 2019 |
Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
Topics: Atrophy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Indoles; Pelvic Organ Prolapse; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Treatment Outcome; Vagina; Vaginal Diseases; Vulva; Vulvar Diseases | 2014 |
An update on non-uterine gynaecological effects on raloxifene.
Topics: Atrophy; Female; Genital Diseases, Female; Humans; Pelvic Floor; Prognosis; Prolapse; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Urinary Retention | 2002 |
3 trial(s) available for raloxifene hydrochloride and Atrophy
| Article | Year |
|---|---|
Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy.
Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Humans; Middle Aged; Postmenopause; Probability; Raloxifene Hydrochloride; Reference Values; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome; Vagina; Vaginal Creams, Foams, and Jellies; Vaginal Diseases | 2003 |
Short-term urogenital effects of raloxifene, tamoxifen, and estrogen.
Topics: Aged; Atrophy; Double-Blind Method; Estradiol; Estrogens; Estrogens, Conjugated (USP); Estrone; Female; Humans; Menopause; Middle Aged; Placebos; Raloxifene Hydrochloride; Tamoxifen; Urethra; Uterine Prolapse; Vagina | 2003 |
Effect of raloxifene on sexual function in postmenopausal women.
Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Double-Blind Method; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Sexuality; Surveys and Questionnaires; Treatment Outcome; Vagina; Vaginal Creams, Foams, and Jellies; Vaginal Diseases | 2003 |
4 other study(ies) available for raloxifene hydrochloride and Atrophy
| Article | Year |
|---|---|
Differential effects of 17beta-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency.
Topics: Animals; Atrophy; Bone Density Conservation Agents; Calcitriol; Calcium; Cholesterol; Chronic Disease; Estradiol; Estrogens; Female; Hyperplasia; Kidney Diseases; Mammary Glands, Animal; Organ Size; Parathyroid Hormone; Phosphorus; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tibia; Uterus | 2010 |
What happened to WHI: menopausal hormonal therapy in 2012.
Topics: Atrophy; Breast Neoplasms; Endometrial Neoplasms; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Estrogens; Female; Hot Flashes; Humans; Menopause; Middle Aged; Norpregnenes; Patient Selection; Raloxifene Hydrochloride; Vagina | 2012 |
Selective estrogen receptor modulation attenuates proteinuria-induced renal tubular damage by modulating mitochondrial oxidative status.
Topics: Animals; Apoptosis; Atrophy; Cells, Cultured; Cytokines; Disease Models, Animal; Female; Fibrosis; Gene Expression Regulation; Glomerulonephritis; Humans; Inflammasomes; Inflammation Mediators; Kidney Tubules, Proximal; Lipid Peroxidation; Macrophages; Mice; Mice, Inbred ICR; Mitochondria; Nephritis, Hereditary; NF-kappa B; Ovariectomy; Oxidation-Reduction; Oxidative Stress; Proteinuria; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2013 |
New drugs, new effects, new problems.
Topics: Atrophy; Drug Interactions; Estradiol; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Medication Errors; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Vaginitis | 2000 |